Press releases
Dextech Medical AB Annual report 190701 – 200630
3 September, 2020Download annual report below. Dextech Annual report 190701-200630
Year-end report July 1, 2019 – June 30, 2020
28 August, 2020By “Company” or “DexTech” is meant DexTech Medical AB with organization number 556664-6203. Summary of the Fourth Quarter (April 1 – June 30, 2020) Net sales amounted to MSEK 0,0 […]
DexTech’s Phase IIb study for OsteoDex ends with positive follow-up results
12 June, 2020The company’s randomized Phase IIb study for the treatment of bone metastatic castration-resistant prostate cancer (mCRPC) has now been completed with 2-year follow-up results from the last patients. The primary […]
DexTech’s Phase IIb study for OsteoDex concludes with positive follow-up results
28 May, 2020The company’s Phase IIb study for the treatment of skeletal metastatic castration-resistant prostate cancer (mCRPC) shows continued promising follow-up data and confirms previously announced partial results. Formalities in the form […]
Interim report July 1, 2019 – March 31, 2020
6 May, 2020By “Company” or “DexTech” is meant DexTech Medical AB with organization number 556664-6203. Summary of the Nine-Month period (2019-07-01 – 2020-03-31) Net sales amounted to MSEK 0,0 (0,0) Operating profit/loss […]
Half Year report July 1 – December 31, 2019
31 January, 2020By “Company” or “DexTech” is meant DexTech Medical AB with organization number 556664-6203. Summary of the First Half Year (2019-07-01 – 2019-12-31) • Net sales amounted to MSEK 0.0 (0.0) […]
Interim report July 1 – September 30, 2019
24 October, 2019By “Company” or “DexTech” is meant DexTech Medical AB with organization number 556664-6203. First Quarter Summary (July – September 2019) Net sales amounted to MSEK 0,0 (0,0) Operating profit/loss […]
Report from the annual general meeting in DexTech Medical AB on 17 October 2019
17 October, 2019Today, October 17, 2019, the Annual General Meeting of DexTech Medical AB was held. Below is a summary of the decisions that were made. All decisions were made with the […]
Promising follow-up results from DexTech’s Phase IIb study for OsteoDex
14 October, 2019The company’s phase IIb study for the treatment of advanced prostate cancer i.e. castration resistant metastatic prostate cancer (mCRPC), can report promising follow-up results as of October 14. Patients are […]
Dextech Medical AB Annual report 180701 – 190630
19 September, 2019Download annual report below. Dextech Annual Report 180701-190630